xCellSense®: Drug Combination Optimization

Rank Your Combinations in Live Patient Cells

xCellSense® quantifies synergy and antagonism for your asset paired with standard-of-care backbones — measured in primary primary blood cancer-derived cells.
Scored with established reference models — Bliss, Loewe, ZIP, HSA — with an ML layer integrating across the full dose-response surface to produce a single regimen ranking.

Request Scientific Consultation

The combination question, answered functionally

Combination benefit varies patient to patient, and cell lines routinely predict synergy that doesn't hold in primary cells. xCellSense® tests your asset alone and paired with standard-of-care backbones in the same primary sample — so every comparison reflects drug effect, not donor-to-donor variability.

You receive quantitative synergy and antagonism scores from established reference models and integrated into a unified ranking to guide the selection of potential combinations for clinical advancement.

A male scientist looking through a microscope

What we measure

*Each combination is evaluated concurrently with single-agent arms and vehicle controls within the same patient sample

Synergy matrices
Quantitative scoring by established reference models — Bliss, Loewe, ZIP, HSA — with explicit antagonism detection.

Combination dose-response
Full dose-response across the combination matrices, measured in each primary patient sample.

Responder Fraction
Proportion of samples demonstrating combination benefit, categorized by sensitive versus resistant groups, which informs enrichment hypotheses.

ML-integrated ranking
Our integration models were developed using ex vivo drug-response datasets paired with clinical outcomes.

Why it de-risks development

Identify and exclude antagonistic pairings before they advance into a clinical trial arm
Define the concentration range where synergy occurs and rank potential combination partners.
Support a defensible translational rationale for development plans and partnering discussions

Key Deliverables

Combination dose-response surfaces across concentration gradients, per primary sample

Synergy and antagonism quantified by established reference models, with antagonistic regions localized

Response heterogeneity across samples, distinguishing sensitive from resistant phenotypes

Interpretation memo and underlying dataset, delivered in weeks, not months

OTHER SERVICES

Drug Combination Optimization Drug Resistance Profiling Biomarker Validation Immunotherapy Translational

Let's Talk

Scope a Combination Study on primary patient cells

A scientist — not a sales desk — will scope a tailored study and return a design and timeline.

Resources
& Links

Frequently Asked Questions



Speak to a Scientist

